Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | RXRA | P19793 | 3/20 | 0.42 |
| ▸ | RXRB | P28702 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770707 | 0.90 | RXRA (0.53) | TP53FFAR1RXRARXRBTSHR | |
| SCHEMBL5773924 | 0.85 | MAPT (0.44) | TSHRALPL | |
| SCHEMBL5772921 | 0.84 | RXRA (0.53) | FFAR1RXRARXRBRXRGNR4A2 | |
| SCHEMBL5776428 | 0.81 | SIRT2 (0.39) | SMN1; SMN2ALPL | |
| SCHEMBL5772923 | 0.81 | TSHR (0.55) | FFAR1RXRARXRBTSHRFFAR4 | |
| SCHEMBL5775506 | 0.80 | AHR (0.36) | TP53SMN1; SMN2TSHR | |
| SCHEMBL5773615 | 0.79 | RXRA (0.56) | FFAR1RXRARXRBTSHRRXRG | |
| SCHEMBL5770527 | 0.78 | RXRA (0.53) | FFAR1RXRARXRBTSHRGPR17 | |
| SCHEMBL5773868 | 0.77 | RXRA (0.53) | FFAR1RXRARXRBTSHRRXRG | |
| SCHEMBL5774812 | 0.77 | FFAR1 (0.42) | FFAR1RXRARXRBTSHRGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | TP53 4371/4885SMN1; SMN2 3383/4885FFAR1 178/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | TP53 4446/4885SMN1; SMN2 2449/4885FFAR1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.